Video

Dr. Jhaveri on Outlining First-Line Treatment in HER2+ Breast Cancer

Komal Jhaveri, MD, FACP, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

Komal Jhaveri, MD, FACP, attending physician, Memorial Sloan Kettering Cancer Center, clinical director of the Early Drug Development Service, assistant professor of medicine, Weill Cornell Medical College, discusses the importance of outlining the first-line treatment course for patients with HER2-positive breast cancer.

For patients with newly diagnosed de novo metastatic HER2-positive breast cancer, outlining the potential plan for their entire course of treatment can be overwhelming, says Jhaveri. As such, it may be beneficial to focus on first-line therapy. The same can be true for patients who develop advanced-stage disease where treatment options are more palliative than curative, Jhaveri explains.

One standard frontline option for patients with advanced-stage disease is the combination of paclitaxel or docetaxel, trastuzumab (Herceptin), and pertuzumab (Perjeta), Jhaveri says.

Typically, patients receive the chemotherapy backbone until maximal response, Jhaveri explains. This occurs after about 6 months of weekly paclitaxel or 6 to 8 cycles of docetaxel. Then, patients receive maintenance trastuzumab/pertuzumab, Jhaveri concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity